UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/597,938	08/11/2006	Dimitrios Pantelidis	53233-00021 NAT	8160
10/597,938 08/11/2006 Dimitrios Pantelidis 48423 7590 06/24/2010 K&L Gates LLP ATTN: Michelle S. Glasky, Ph.D. 1900 MAIN STREET SUITE 600 IRVINE, CA 92614-7319	EXAMINER			
	•	AZPURU, CARLOS A		
SUITE 600			ART UNIT	PAPER NUMBER
			1615	
			NOTIFICATION DATE	DELIVERY MODE
			06/24/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ocipgroup@klgates.com michelle.glasky@klgates.com

	Application No.	Applicant(s)				
	10/597,938	PANTELIDIS ET AL.				
Office Action Summary	Examiner	Art Unit				
	Carlos A. Azpuru	1615				
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>25 M</u>	arch 2010					
	action is non-final.					
·=	'=					
closed in accordance with the practice under E						
Disposition of Claims						
4)⊠ Claim(s) <u>1-41</u> is/are pending in the application.						
4a) Of the above claim(s) <u>22-41</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1,14 and 20</u> is/are rejected.						
7)⊠ Claim(s) <u>2-13, 15-19 and 21</u> is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correct	on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).				
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(c)						
Attachment(s) 1) \(\sum \) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate				
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>08112006,10062006, 07082009</u> .	5) Notice of Informal P 6) Other:	atent Application				

DETAILED ACTION

Receipt is acknowledged of the information disclosure statements filed 08/11/2006, 10/06/2006 and 07/08/2009.

Election/Restrictions

Applicant's election with traverse of Group I in the reply filed on 03/25/2010 is acknowledged. The traversal is on the ground(s) that Group I is defined as a triblock copolymer-template based mesoporous oxide. This is not found persuasive because the independent claim as well as claims 1-4, 7-21 do not require this feature.

The requirement is still deemed proper and is therefore made FINAL.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by WO 00/25841 (Brandau et al).

Brandau et al disclose a mesoporous ccoating of aluminum oxide with cavities (reservoirs) which contain a bioactive to be released. The instant claim is anticipated by Brandau et al.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 14 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for stents, does not reasonably provide enablement for all drug delivery systems with this composition. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Paragraph [0066] is specific to stents having this claimed dosage range. No other drug delivery systems are set out in this paragraph. Correction is requested.

Claim 20 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The range set out in claim 20 is not supported by the specification as set out in paragraph [0066]. Correction is requested.

During the search for this invention, interconnected pores were not found. It is

therefore suggested that claim 1 be amended to incorporate this limitation in order to

place claims 1-21 in condition for allowance.

Claims 2-13, 14-19, and 21 are objected to as dependent upon a rejected base

claim.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Carlos A. Azpuru whose telephone number is (571) 272-

0588. The examiner can normally be reached on Tu-Fri, 6:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Robert A. Wax can be reached on (571) 272-0623. The fax phone number

for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/597,938 Page 5

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Carlos A. Azpuru/ Primary Examiner, Art Unit 1615 Carlos A. Azpuru Primary Examiner Art Unit 1615

caz